CliffBio
biologic

Unloxcyt

cosibelimab-ipdl

Loss of exclusivityDecember 2036projected — 12-year biologic exclusivity estimate
CompanyCheckpoint Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameUnloxcyt
Active ingredientcosibelimab-ipdl
Strength300MG/5ML (60MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2024
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.